Related Experiment Video
Updated: May 5, 2026

Reprogramming Induced Pluripotent Stem Cell Lines from Frozen Buffy Coat Samples
Published on: April 10, 2026
Human induced pluripotent stem cells from basic research to potential clinical applications in cancer
Teresa de Souza Fernandez1, Cecilia de Souza Fernandez, André Luiz Mencalha
1National Cancer Institute (INCA), Bone Marrow Transplantation Center (CEMO), Laboratory Division, 20230-130 Rio de Janeiro, RJ, Brazil.
Abstract:
The human induced pluripotent stem cells (hiPSCs) are derived from a direct reprogramming of human somatic cells to a pluripotent stage through ectopic expression of specific transcription factors. These cells have two important properties, which are the self-renewal capacity and the ability to differentiate into any cell type of the human body. So, the discovery of hiPSCs opens new opportunities in biomedical sciences, since these cells may be useful for understanding the mechanisms of diseases in the production of new diseases models, in drug development/drug toxicity tests, gene therapies, and cell replacement therapies. However, the hiPSCs technology has limitations including the potential for the development of genetic and epigenetic abnormalities leading to tumorigenicity. Nowadays, basic research in the hiPSCs field has made progress in the application of new strategies with the aim to enable an efficient production of high-quality of hiPSCs for safety and efficacy, necessary to the future application for clinical practice. In this review, we show the recent advances in hiPSCs' basic research and some potential clinical applications focusing on cancer. We also present the importance of the use of statistical methods to evaluate the possible validation for the hiPSCs for future therapeutic use toward personalized cell therapies.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
iPS Cell Differentiation
Stem Cell Culture
EPS and iPS Cells in Disease Research

